Analytical Data
-
Gene name
CDK4-CCND3
- Application
-
Alternative Names
Cyclin-dependent kinase 4 Cyclin-dependent kinase 4, isoform CRA_c
-
Species
Human
-
Source
Baculovirus
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11802
-
Expression Region
2-303aa
-
Molecular Weight
35.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK4 (Cyclin-Dependent Kinase 4) and CCND3 (Cyclin D3) are crucial components of the cell cycle regulation machinery, playing significant roles in the transition from the G1 phase to the S phase of the cell cycle. Aberrations in this regulatory pathway are associated with various cancers, making it a focus of intense research. The CDK4-CCND3 complex is integral in promoting cell proliferation, and understanding its structure and function could provide insights into tumorigenesis and potential therapeutic targets. Researchers have developed recombinant proteins of CDK4 and CCND3 to study their interactions, enzymatic activity, and regulatory mechanisms in detail. These studies often utilize techniques such as X-ray crystallography and high-performance affinity chromatography to explore the conformational dynamics and binding affinities of the complex. Furthermore, exploring the specific roles of post-translational modifications on these proteins can unveil how they contribute to cancer progression. Investigating CDK4-CCND3 interactions also holds promise for developing CDK inhibitors as targeted cancer therapies, as these compounds could effectively disrupt aberrant cell cycle progression seen in malignancies. Overall, the characterization of CDK4-CCND3 recombinant proteins is pivotal for uncovering novel insights into cell cycle regulation and cancer therapeutics.
